Skip to content

Closed-loop Control of Glucose Levels After Meal Intake in Adults With Type 1 Diabetes

An Open-label, Randomized, Three-way, Cross-over Study to Compare the Efficacy of Closed-loop Operation Combined With Meal-and-carbohydrate-announcement Closed-loop Operation Combined With Meal-announcement, and Conventional Pump Therapy in Regulating Glucose Levels in Adults With Type 1 Diabetes

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01930097
Enrollment
12
Registered
2013-08-28
Start date
2013-08-31
Completion date
2014-02-28
Last updated
2014-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

Type 1 diabetes, Hypoglycemia, Insulin, Glucagon, Closed-loop system, Artificial pancreas, Carbohydrate counting

Brief summary

Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosage based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormones: insulin and glucagon. The objective of this project is to assess whether a dual-hormone closed-loop strategy would alleviate the burden of carbohydrate counting from patients with type 1 diabetes (T1D) without a significant degradation in post-meal glucose control. Our primary hypothesis is that meal-announcement strategy (pre-meal CHO-independent bolus) is equivalent to meal-and-carbohydrate-announcement strategy (full CHO-matching bolus) during closed-loop regulation of glucose levels in adults with T1D. Our secondary hypothesis is that closed-loop strategy with meal-announcement strategy (pre-meal CHO-independent bolus) or meal-and-carbohydrate-announcement strategy (full CHO-matching bolus) is better than conventional pump treatment in regulation of glucose levels in adults with T1D.

Detailed description

Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormone: insulin and glucagon. Each patient will be admitted three times to a clinical research facility. In the meal-and-carbohydrate-announcement visit, patients will eat 3 meals accompanied with a matching insulin bolus (depending on the carbohydrate content of the meal) and glucose levels will be subsequently regulated using dual-hormone closed-loop system. In the meal-announcement visit, patients will eat the 3 same meals but will inject only a partial insulin bolus (not depending on carbohydrate content of the meal) and the remaining needed insulin will be delivered based on glucose sensor excursions as part of closed-loop operation. In the control visit, patients will use conventional pump therapy to regulate glucose levels.

Interventions

OTHER14 hours intervention

Subjects will be admitted at the IRCM at 6:30. Subjects will be asked to fast from midnight. At 8:00, a standardized (50g CHO for males; 30g CHO for females) meal will be served. At 12:00, a standardized (120g CHO for males; 90g CHO for females) meal will be served. At 17:00, a standardized (70g CHO for males; 50g CHO for females) meal will be served. Between meals, patients will be allowed to do sedentary activities (reading, watching television, and playing video games, etc).

Sponsors

Juvenile Diabetes Research Foundation
CollaboratorOTHER
Institut de Recherches Cliniques de Montreal
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Males and females ≥ 18 years of old. * Clinical diagnosis of type 1 diabetes for at least one year. * The subject will have been on insulin pump therapy for at least 3 months. * Last (less than 3 months) HbA1c ≤ 12%.

Exclusion criteria

* Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator. * Recent (\< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. * Ongoing pregnancy. * Severe hypoglycemic episode within two weeks of screening. * Medication likely to affect with the interpretation of the results because of their well known impact on gastric emptying: Motilium®, Prandase®, Victoza®, Byetta® and Symlin®. * Known or suspected allergy to the trial products, meal contents including nuts, peanuts, dairy products or eggs. * Unusual nutritional habits (e.g. vegetarians) * Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator. * Failure to comply with team's recommendations (e.g. not willing to eat snack, not willing to change pump parameters, etc). * Unreliable carbohydrate counting or lack of insulin to carbohydrate ratios * Problems with venous access

Design outcomes

Primary

MeasureTime frameDescription
The positive incremental area under the curve of postprandial glucose excursions4 hours after meal intakeThe positive incremental area under the curve (IAUC, as compared to pre-meal glucose value) of the 4-hr postprandial glucose excursions for the breakfast, lunch and dinner meals.

Secondary

MeasureTime frame
Mean plasma glucose8h00 to 21h00
Incremental two hours postprandial glucose2 hours after meal intake
Incremental postprandial peak-glucose values8h00 to 21h00
Percentage of time of plasma glucose levels between 4.0 and 10.0 mmol/L8h00 to 21h00
Percentage of time of plasma glucose levels spent above 10.0 mmol/L8h00 to 21h00
Percentage of time of plasma glucose levels spent below 4.0 mmol/L8h00 to 21h00
Total insulin delivery8h00 to 21h00
Mean plasma insulin concentration8h00 to 21h00
Standard deviation of glucose levels8h00 to 21h00
Percentage of time of plasma glucose concentrations below 3.5 mmol/L8h00 to 21h00
Percentage of time of plasma glucose concentrations above 14 mmol/L8h00 to 21h00
Mean plasma glucagon concentration8h00 to 21h00
Number of patients experiencing hypoglycemia requiring oral treatment8h00 to 21h00
Incremental area under the curve of the 4-hr postprandial glucose excursions but the reference glucose is set to 5.0 mmol/L if premeal glucose is less than 5.0 mmol/L.4 hours after meal intake
Total glucagon delivery8h00 to 21h00

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026